TY - JOUR
T1 - Quality metrics in adult spinal deformity surgery over the last decade
T2 - a combined analysis of the largest prospective multicenter data sets
AU - on behalf of the International Spine Study Group (ISSG) and European Spine Study Group (ESSG)
AU - Pellisé, Ferran
AU - Serra-Burriel, Miquel
AU - Vila-Casademunt, Alba
AU - Gum, Jeffrey L.
AU - Obeid, Ibrahim
AU - Smith, Justin S.
AU - Kleinstück, Frank S.
AU - Bess, Shay
AU - Pizones, Javier
AU - Lafage, Virginie
AU - Pérez-Grueso, Francisco Javier S.
AU - Schwab, Frank J.
AU - Burton, Douglas C.
AU - Klineberg, Eric O.
AU - Shaffrey, Christopher I.
AU - Alanay, Ahmet
AU - Ames, Christopher P.
N1 - Funding Information:
The ISSG Foundation receives funding support from DePuy Synthes, K2M, NuVasive, Orthofix, and Zimmer Biomet. The ESSG receives funding support from DePuy Synthes and Medtronic. Dr. Pellisé is a consultant for Medtronic and DePuy Spine, and he also received clinical or research support for the study described (includes equipment or material) from those companies. He is a board member of the Scoliosis Research Society and an associate board member of the AO Spine Deformity Knowledge Forum. Dr. Gum is an employee of Norton Healthcare and a consultant for Medtronic, Acuity, K2M/Stryker, NuVasive, and Mazor. He is in the speaker’s bureau for DePuy, and receives royalties from Acuity and NuVasive. He has received honoraria from Picira Pharmaceuticals, Baxter, Broadwater, and NASS. He has received clinical or research support for the study described (includes equipment or material) from Integra, Intellirod Spine Inc., Pfizer, ISSG, NuVasive, Norton Healthcare, Texas Scottish Rite Hospital, Alan L. and Jacqueline B. Stuart Research, Cerepedics Inc., SRS, and Medtronic. He reports direct stock ownership in Cingulate Therapeutics, and holds a patent with Medtronic. He is on the advisory/editorial boards of K2M/ Stryker, Medtronic, and National Spine Health. Dr. Obeid is a consultant for DePuy Synthes and Medtronic. He has received clinical or research support for the study described (includes equipment or material) from DePuy Synthes. He receives royalties from Alphatec, Spineart, and Clariance. Dr. Smith is a consultant for Zimmer Biomet, NuVasive, Stryker, DePuy, Cerapedics, and Carlsmed. He reports direct stock ownership in NuVasive and Alphatec, and he receives royalties from Zimmer Biomet, NuVasive, and Thieme. He receives support of a non–study-related clinical or research effort that he oversees from DePuy Synthes, NuVasive, and AO Spine. He receives clinical or research support for the study described (includes equipment or material) from DePuy Synthes. AO Spine has provided him with fellowship support. Dr. Kleinstück is in the speaker’s bureau for DePuy
Funding Information:
Synthes. Dr. Bess is a consultant for K2M Stryker, and is a patent holder with K2M Stryker and NuVasive. He receives clinical or research support for the study described (includes equipment or material) from DePuy Synthes, ISSGF, K2M Stryker, and NuVasive. He receives support of a non–study-related clinical or research effort that he oversees from Medtronic, Globus, and SI Bone. He receives royalties from K2M Stryker. Dr. Pizones is a consultant for Medtronic. Dr. Lafage is a consultant for Globus Medical. She receives royalties from NuVasive and honoraria from DePuy Synthes and J&J. Dr. Schwab is a consultant for Zimmer Biomet, MSD, and Globus Medical. He receives royalties from MDS and Zimmer Biomet. He is on the executive committee of the ISSG. Dr. Burton is a patent holder with DePuy, and has direct stock ownership in Progenerative Medica. He receives clinical or research support for the study described (includes equipment or material) from the ISSG Foundation. Dr. Klineberg is a consultant for DePuy Synthes, Stryker, and Medicrea/ Medtronic. He receives honoraria and a fellowship grant from AO Spine. Dr. Shaffrey is a consultant for Medtronic, NuVasive, and SI Bone. He has direct stock ownership in NuVasive, and is a patent holder with Medtronic, NuVasive, and Zimmer Biomet. He receives royalties from Medtronic, NuVasive, and SI Bone. Dr. Ames is an employee of UCSF. He receives royalties from Stryker, DePuy Synthes, Biomet Zimmer Spine, NuVasive, Next Orthosurgical, K2M, and Medicrea. He is a consultant for DePuy Synthes, Medtronic, Medicrea, and K2M. He conducts research for Titan Spine, DePuy Synthes, and ISSG; is on the editorial board of Operative Neurosurgery; receives grant funding from SRS; is on the executive committee for ISSG; and is a director for Global Spinal Analytics.
Publisher Copyright:
© AANS 2022, except where prohibited by US copyright law.
PY - 2022/2
Y1 - 2022/2
N2 - OBJECTIVE The reported rate of complications and cost of adult spinal deformity (ASD) surgery, associated with an exponential increase in the number of surgeries, cause alarm among healthcare payers and providers worldwide. The authors conjointly analyzed the largest prospective available ASD data sets to define trends in quality-of-care indicators (complications, reinterventions, and health-related quality of life [HRQOL] outcomes) since 2010. METHODS This is an observational prospective longitudinal cohort study. Patients underwent surgery between January 2010 and December 2016, with > 2 years of follow-up data. Demographic, surgical, radiological, and HRQOL (i.e., Oswestry Disability Index, SF-36, Scoliosis Research Society-22r) data obtained preoperatively and at 3, 6, 12, and 24 months after surgery were evaluated. Trends and changes in indicators were analyzed using local regression (i.e., locally estimated scatterplot smoothing [LOESS]) and adjusted odds ratio (OR). RESULTS Of the 2286 patients included in the 2 registries, 1520 underwent surgery between 2010 and 2016. A total of 1151 (75.7%) patients who were treated surgically at 23 centers in 5 countries met inclusion criteria. Patient recruitment increased progressively (2010–2011 vs 2015–2016: OR 1.64, p < 0.01), whereas baseline clinical characteristics (age, American Society of Anesthesiologists class, HRQOL scores, sagittal deformity) did not change. Since 2010 there has been a sustained reduction in major and minor postoperative complications observed at 90 days (major: OR 0.59; minor: OR 0.65; p < 0.01); at 1 year (major: OR 0.52; minor: 0.75; p < 0.01); and at 2 years of follow-up (major: OR 0.4; minor: 0.80; p < 0.01) as well as in the 2-year reintervention rate (OR 0.41, p < 0.01). Simultaneously, there has been a slight improvement in the correction of sagittal deformity (i.e., pelvic incidence–lumbar lordosis mismatch: OR 1.11, p = 0.19) and a greater gain in quality of life (i.e., Oswestry Disability Index 26% vs 40%, p = 0.02; Scoliosis Research Society-22r, self-image domain OR 1.16, p = 0.13), and these are associated with a progressive reduction of surgical aggressiveness (number of fused segments: OR 0.81, p < 0.01; percent pelvic fixation: OR 0.66, p < 0.01; percent 3-column osteotomies: OR 0.63, p < 0.01). CONCLUSIONS The best available data show a robust global improvement in quality metrics in ASD surgery over the last decade. Surgical complications and reoperations have been reduced by half, while improvement in disability increased and correction rates were maintained, in patients with similar baseline characteristics.
AB - OBJECTIVE The reported rate of complications and cost of adult spinal deformity (ASD) surgery, associated with an exponential increase in the number of surgeries, cause alarm among healthcare payers and providers worldwide. The authors conjointly analyzed the largest prospective available ASD data sets to define trends in quality-of-care indicators (complications, reinterventions, and health-related quality of life [HRQOL] outcomes) since 2010. METHODS This is an observational prospective longitudinal cohort study. Patients underwent surgery between January 2010 and December 2016, with > 2 years of follow-up data. Demographic, surgical, radiological, and HRQOL (i.e., Oswestry Disability Index, SF-36, Scoliosis Research Society-22r) data obtained preoperatively and at 3, 6, 12, and 24 months after surgery were evaluated. Trends and changes in indicators were analyzed using local regression (i.e., locally estimated scatterplot smoothing [LOESS]) and adjusted odds ratio (OR). RESULTS Of the 2286 patients included in the 2 registries, 1520 underwent surgery between 2010 and 2016. A total of 1151 (75.7%) patients who were treated surgically at 23 centers in 5 countries met inclusion criteria. Patient recruitment increased progressively (2010–2011 vs 2015–2016: OR 1.64, p < 0.01), whereas baseline clinical characteristics (age, American Society of Anesthesiologists class, HRQOL scores, sagittal deformity) did not change. Since 2010 there has been a sustained reduction in major and minor postoperative complications observed at 90 days (major: OR 0.59; minor: OR 0.65; p < 0.01); at 1 year (major: OR 0.52; minor: 0.75; p < 0.01); and at 2 years of follow-up (major: OR 0.4; minor: 0.80; p < 0.01) as well as in the 2-year reintervention rate (OR 0.41, p < 0.01). Simultaneously, there has been a slight improvement in the correction of sagittal deformity (i.e., pelvic incidence–lumbar lordosis mismatch: OR 1.11, p = 0.19) and a greater gain in quality of life (i.e., Oswestry Disability Index 26% vs 40%, p = 0.02; Scoliosis Research Society-22r, self-image domain OR 1.16, p = 0.13), and these are associated with a progressive reduction of surgical aggressiveness (number of fused segments: OR 0.81, p < 0.01; percent pelvic fixation: OR 0.66, p < 0.01; percent 3-column osteotomies: OR 0.63, p < 0.01). CONCLUSIONS The best available data show a robust global improvement in quality metrics in ASD surgery over the last decade. Surgical complications and reoperations have been reduced by half, while improvement in disability increased and correction rates were maintained, in patients with similar baseline characteristics.
KW - Adult spinal deformity
KW - Quality metrics
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85126850426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126850426&partnerID=8YFLogxK
U2 - 10.3171/2021.3.SPINE202140
DO - 10.3171/2021.3.SPINE202140
M3 - Article
C2 - 34598152
AN - SCOPUS:85126850426
VL - 36
SP - 226
EP - 234
JO - Journal of neurosurgery. Spine
JF - Journal of neurosurgery. Spine
SN - 1547-5654
IS - 2
ER -